Wareham Development announced that it has executed a lease for 78,000 square feet over several floors of the newly-constructed 265,000 square foot EmeryStation West laboratory/office/transit project at its EmeryStation research campus in Emeryville.

Novartis Institutes for Biomedical Research (NIBR), which is focused on the discovery and early development of definitive therapies for life-threatening diseases, plans to move the Novartis Institute for Tropical Diseases and its global drug discovery teams focused on drugging “undruggable” targets in collaboration with the Novartis-Berkeley Center for Proteomics and Chemistry Technologies into a new 78,000 SF office and laboratory on the eighth and ninth floors at EmeryStation West later this year.

Switzerland-based company Novartis has had an Emeryville presence since it bought the Chiron Corporation, another long-term Wareham tenant, over a decade ago.

Geoffrey B. Sears, Wareham partner said, “Several divisions of Novartis have been domiciled in various Wareham properties over the years. We are delighted to continue the relationship and welcome NIBR to EmeryStation West.”

Wareham Development was represented by the Kidder Mathews team of Timothy Mason, James Bennett and Eric Bluestein. Novartis was represented by Newmark Knight Frank.